메뉴 건너뛰기




Volumn 47, Issue 2, 2008, Pages 176-186

Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis

Author keywords

[No Author keywords available]

Indexed keywords

ALOE VERA EXTRACT; ALPHA TOCOPHEROL; ANTIINFECTIVE AGENT; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CYCLOPHOSPHAMIDE; DIMETHYL SULFOXIDE; DOCETAXEL; DOXORUBICIN; EMOLLIENT AGENT; ERLOTINIB; FLUOROURACIL; IMATINIB; LANOLIN; MAGNESIUM SILICATE; MITOTANE; NAVELBINE; NICOTINE; PETROLATUM; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDOXINE; QUINOLINOL DERIVATIVE; SORAFENIB; STEM CELL FACTOR RECEPTOR; STEROID; SUNITINIB; VASCULOTROPIN RECEPTOR;

EID: 38349102230     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701765675     Document Type: Review
Times cited : (174)

References (53)
  • 1
    • 0036401105 scopus 로고    scopus 로고
    • Wilhelm S CD: Bay 43-9006: Preclinical data. Curr Pharm Des 2002;8:2255-7.
    • Wilhelm S CD: Bay 43-9006: Preclinical data. Curr Pharm Des 2002;8:2255-7.
  • 2
    • 20044382799 scopus 로고    scopus 로고
    • Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor bay 43-9006 in patients with advanced refractory solid tumors
    • Strumberg D RH, Hilger R, et al. Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor bay 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72.
    • (2005) J Clin Oncol , vol.23 , pp. 965-972
    • Strumberg, D.R.1    Hilger, R.2
  • 3
    • 33744984843 scopus 로고    scopus 로고
    • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
    • Ratain M ET, Stadler W et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
    • (2006) J Clin Oncol , vol.24 , pp. 2505-2512
    • Ratain, M.E.1    Stadler, W.2
  • 4
    • 33748913369 scopus 로고    scopus 로고
    • Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma
    • 364s Abstract
    • Gatzemeier U. GB FF, Simantov R, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. ASCO annual meeting Atlanta, Georgia. J Clin Oncol 2006;24:364s (Abstract #7002).
    • (2006) ASCO annual meeting Atlanta, Georgia. J Clin Oncol , vol.24 , Issue.7002
    • Gatzemeier, U.G.F.1    Simantov, R.2
  • 5
    • 33749017926 scopus 로고    scopus 로고
    • Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
    • Ghassan K LS, Sergio R et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300.
    • (2006) J Clin Oncol , vol.24 , pp. 4293-4300
    • Ghassan, K.L.1    Sergio, R.2
  • 6
    • 33746649779 scopus 로고    scopus 로고
    • Phase I study of sorafenib, a raf kinase and vegfr inhibitor, combined with irinotecan in advanced solid tumors
    • Steinbild S BF, Gmehling D et al. Phase I study of sorafenib, a raf kinase and vegfr inhibitor, combined with irinotecan in advanced solid tumors. Proc Am Soc Clin Oncol 2005;23:3115a.
    • (2005) Proc Am Soc Clin Oncol , vol.23
    • Steinbild, S.B.1    Gmehling, D.2
  • 7
    • 38349179448 scopus 로고    scopus 로고
    • Eisen T AT, Gore ME et al. Phase I trial of sorafenib combined with dacarbazine in metastatic melanoma patients. Proc Am Soc Clin Oncol 2005;23:7508a.
    • Eisen T AT, Gore ME et al. Phase I trial of sorafenib combined with dacarbazine in metastatic melanoma patients. Proc Am Soc Clin Oncol 2005;23:7508a.
  • 8
    • 0020329356 scopus 로고
    • Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous lekemia
    • Burgdorf W GW, Ganick R. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous lekemia. Ann Intern Med 1982;97:61-2.
    • (1982) Ann Intern Med , vol.97 , pp. 61-62
    • Burgdorf, W.G.1    Ganick, R.2
  • 9
    • 0021710953 scopus 로고
    • Chemotherapy associated palmar-plantar erythrodysesthesia syndrome
    • Lokich J MC. Chemotherapy associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984;101:789-800.
    • (1984) Ann Intern Med , vol.101 , pp. 789-800
    • Lokich, J.M.1
  • 10
    • 0345596364 scopus 로고    scopus 로고
    • Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors
    • MetaAnalysis Group in Cancer
    • MetaAnalysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 1998;16:3537-41.
    • (1998) J Clin Oncol , vol.16 , pp. 3537-3541
  • 11
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • Escudier B ET, Stadler W, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 2007;356:125-34.
    • (2007) New Engl J Med , vol.356 , pp. 125-134
    • Escudier, B.E.1    Stadler, W.2
  • 13
    • 0022992740 scopus 로고
    • Meta-analysis in clinical trials
    • DerSimonian R LN. Meta-analysis in clinical trials. Control Clin Trial 1986;7:177-88.
    • (1986) Control Clin Trial , vol.7 , pp. 177-188
    • DerSimonian, R.L.1
  • 14
    • 0030693603 scopus 로고    scopus 로고
    • Quantitative synthesis in systematic reviews
    • Lau J IJ, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-6.
    • (1997) Ann Intern Med , vol.127 , pp. 820-826
    • Lau, J.I.1    Schmid, C.H.2
  • 15
    • 33748325763 scopus 로고    scopus 로고
    • Eiesen T AT, Flaherty K, et al. Sorafenib in advanced melanoma: A phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581-6.
    • Eiesen T AT, Flaherty K, et al. Sorafenib in advanced melanoma: A phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581-6.
  • 16
    • 38349160860 scopus 로고    scopus 로고
    • Randomized phase II trial of sorafenib vs interferon in treatment-naive patients with advanced renal cell carcinoma
    • Atlanta, Georgia
    • Escudier B Sc DT, Staehler M, et al. Randomized phase II trial of sorafenib vs interferon in treatment-naive patients with advanced renal cell carcinoma. ASCO annual meeting Atlanta, Georgia, 2006.
    • (2006) ASCO annual meeting
    • Escudier, B.S.D.1    Staehler, M.2
  • 17
    • 38349119818 scopus 로고    scopus 로고
    • Wu S EP CS, P. M. Arlen, et al. Bay43-9006 (sorafenib) can lead to improvement of bone lesions in metastatic androgenin-dependent prostate cancer despite rises in serum psa levels. 2006 Prostate Cancer Symposium San Fransisco, 2006 Abstract No:259.
    • Wu S EP CS, P. M. Arlen, et al. Bay43-9006 (sorafenib) can lead to improvement of bone lesions in metastatic androgenin-dependent prostate cancer despite rises in serum psa levels. 2006 Prostate Cancer Symposium San Fransisco, 2006 Abstract No:259.
  • 18
    • 38349160860 scopus 로고    scopus 로고
    • Randomized phase II trial of sorafenib vs interferon in treatment-naive patients with advanced renal cell carcinoma
    • Atlanta, Georgia
    • Escudier B Sc, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, et al. Randomized phase II trial of sorafenib vs interferon in treatment-naive patients with advanced renal cell carcinoma. ASCO annual meeting. Atlanta, Georgia, 2006.
    • (2006) ASCO annual meeting
    • Escudier, B.S.1    Demkow, T.2    Staehler, M.3    Rolland, F.4    Negrier, S.5    Hutson, T.E.6
  • 19
    • 38349141371 scopus 로고    scopus 로고
    • D'Adamo DR KM, Schuetze S, et al. A multicenter phase II trial of oral sorafenib in non-gist sarcomas ctep trial #7060. ASCO annual meeting Chicago, Illinois. J Clin Oncol 2007;25:545s (Abstract #10001).
    • D'Adamo DR KM, Schuetze S, et al. A multicenter phase II trial of oral sorafenib in non-gist sarcomas ctep trial #7060. ASCO annual meeting Chicago, Illinois. J Clin Oncol 2007;25:545s (Abstract #10001).
  • 20
    • 34548720158 scopus 로고    scopus 로고
    • Sorafenib improves survival in hepatocellular carcinoma: Results of a phase III randomized, placebo-controlled trial
    • 1s Abstract #LBA1
    • Llovet J RS, Mazzaferro V, et al. Sorafenib improves survival in hepatocellular carcinoma: Results of a phase III randomized, placebo-controlled trial. ASCO annual meeting Chicago, Illinois. J Clin Oncol 2007;25:1s (Abstract #LBA1).
    • (2007) ASCO annual meeting Chicago, Illinois. J Clin Oncol , vol.25
    • Llovet, J.R.1    Mazzaferro, V.2
  • 21
    • 38349150169 scopus 로고    scopus 로고
    • The advanced renal cell carcinoma sorafenib(arccs) expanded access program in North America: Safety and efficacy
    • 237s Abstract
    • Figlin R SW, McDermott D, et al. The advanced renal cell carcinoma sorafenib(arccs) expanded access program in North America: Safety and efficacy. ASCO annual meeting Chicago, Illinois. J Clin Oncol 2007;25:237s (Abstract #5011).
    • (2007) ASCO annual meeting Chicago, Illinois. J Clin Oncol , vol.25 , Issue.5011
    • Figlin, R.S.1    McDermott, D.2
  • 22
    • 38349109708 scopus 로고    scopus 로고
    • A phase II trial of sorafenib in patients with metastatic neuroendocrine tumors(net): A phase II consortium (p2c) study
    • 199s Abstract
    • Hobday T RJ, Holen K, et al. A phase II trial of sorafenib in patients with metastatic neuroendocrine tumors(net): A phase II consortium (p2c) study. ASCO annual meeting Chicago, Illinois. J Clin Oncol 2007;25:199s (Abstract #4504).
    • (2007) ASCO annual meeting Chicago, Illinois. J Clin Oncol , vol.25 , Issue.4504
    • Hobday, T.R.1    Holen, K.2
  • 23
    • 32444439875 scopus 로고    scopus 로고
    • Pooled safety analysis of bay 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
    • Strumberg DAA, Hirte H, et al. Pooled safety analysis of bay 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 2006;42:548-56.
    • (2006) Eur J Cancer , vol.42 , pp. 548-556
    • Strumberg, D.A.A.1    Hirte, H.2
  • 24
    • 0033122792 scopus 로고    scopus 로고
    • Capecitabine: Nursing implications of a new oral chemotherapeutic agent
    • Mrozek-Orlowski M FD, Sandborn H, et al. Capecitabine: Nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum 1999;26:753-62.
    • (1999) Oncol Nurs Forum , vol.26 , pp. 753-762
    • Mrozek-Orlowski, M.F.1    Sandborn, H.2
  • 25
    • 25444472043 scopus 로고    scopus 로고
    • Release of doxorubicin in sweat: First step to induce the palmar-plantar erythrodysesthesia syndrome?
    • Jacobi U WE, Schulze P. Release of doxorubicin in sweat: First step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 2005;16:1210-1.
    • (2005) Ann Oncol , vol.16 , pp. 1210-1211
    • Jacobi, U.W.1    Schulze, P.2
  • 26
    • 33846924560 scopus 로고    scopus 로고
    • Hand-foot and stump syndrome to sorafenib
    • Lai S KT, Lacouture M. Hand-foot and stump syndrome to sorafenib. J Clin Oncol 2007;25:341.
    • (2007) J Clin Oncol , vol.25 , pp. 341
    • Lai, S.K.1    Lacouture, M.2
  • 27
    • 33845313345 scopus 로고    scopus 로고
    • The clinical toxicity profile of vascular endothelial growth factor(vegf) and vascular endothelial growth factor receptor(vegfr) targeting angiogenesis inhibitors; a review
    • Eskens F VJ. The clinical toxicity profile of vascular endothelial growth factor(vegf) and vascular endothelial growth factor receptor(vegfr) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42:3127-39.
    • (2006) Eur J Cancer , vol.42 , pp. 3127-3139
    • Eskens, F.V.1
  • 28
    • 21344462378 scopus 로고    scopus 로고
    • Cutaneous side-effects of kinase inhibitors and blocking antibodies
    • Robert C SJ, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
    • (2005) Lancet Oncol , vol.6 , pp. 491-500
    • Robert, C.S.1    Spatz, A.2
  • 29
    • 33749251592 scopus 로고    scopus 로고
    • Increased efficacy and toxicity with combination anti-vegf therapy using sorafenib and bevacizumab
    • Azad N PE, Kohn E, et al. Increased efficacy and toxicity with combination anti-vegf therapy using sorafenib and bevacizumab. ASCO Annual Meeting Atlanta, Georgia. J Clin Oncol 2006;24:3004.
    • (2006) ASCO Annual Meeting Atlanta, Georgia. J Clin Oncol , vol.24 , pp. 3004
    • Azad, N.P.1    Kohn, E.2
  • 30
    • 1442290142 scopus 로고    scopus 로고
    • Combined inhibition of vegf and pdgf signaling enforces tumor vessel regression by interering with pericyte-mediated endothelial cell survival mechanisms
    • Erber R TA, Katsen A, et al. Combined inhibition of vegf and pdgf signaling enforces tumor vessel regression by interering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 2004;18:338-40.
    • (2004) Faseb J , vol.18 , pp. 338-340
    • Erber, R.T.1    Katsen, A.2
  • 31
    • 34247361171 scopus 로고    scopus 로고
    • Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma
    • Tsai K YC, Kuo T, et al. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006;24:5786-8.
    • (2006) J Clin Oncol , vol.24 , pp. 5786-5788
    • Tsai, K.Y.1    Kuo, T.2
  • 32
    • 34547852276 scopus 로고    scopus 로고
    • Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot syndrome')
    • Lorusso D DSA, Carone V, et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot syndrome'). Ann Oncol 2007.
    • (2007) Ann Oncol
    • Lorusso, D.D.1    Carone, V.2
  • 33
    • 0028280287 scopus 로고
    • Epithelial-stromal interactions in basal cell cancer: The pdgf system
    • Ponten F RZ, Nister M, et al. Epithelial-stromal interactions in basal cell cancer: The pdgf system. J Invest Dermatol 1994;102:304-9.
    • (1994) J Invest Dermatol , vol.102 , pp. 304-309
    • Ponten, F.R.1    Nister, M.2
  • 34
    • 0028116487 scopus 로고
    • Expression of c-kit and kit ligand proteins in normal human tissues
    • Lammie A DM, Gerald W, et al. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 1994;42:1417-25.
    • (1994) J Histochem Cytochem , vol.42 , pp. 1417-1425
    • Lammie, A.D.1    Gerald, W.2
  • 35
    • 0028293816 scopus 로고
    • Expression of c-kit ligand in human keratinocytes
    • Morita E LD, Sugiyama M, et al. Expression of c-kit ligand in human keratinocytes. Arch Dermatol Res 1994;286:273-7.
    • (1994) Arch Dermatol Res , vol.286 , pp. 273-277
    • Morita, E.L.1    Sugiyama, M.2
  • 36
    • 38349176975 scopus 로고    scopus 로고
    • Imatinib mesylate causes palmoplantar hyperkeratosis in 3 patients with chronic myeloid leukemia
    • Kawamura T DN, Shimizu A, et al. Imatinib mesylate causes palmoplantar hyperkeratosis in 3 patients with chronic myeloid leukemia. Br J Dermatol 2006;154:1199-219.
    • (2006) Br J Dermatol , vol.154 , pp. 1199-1219
    • Kawamura, T.D.1    Shimizu, A.2
  • 37
    • 38349184317 scopus 로고    scopus 로고
    • Hainsworth JD SJ, Spigel DR, et al. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma (rcc): A minnie pearl cancer research network phase I/II trial. ASCO Annual Meeting Orlando. 2005 Abstract # 4542.
    • Hainsworth JD SJ, Spigel DR, et al. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma (rcc): A minnie pearl cancer research network phase I/II trial. ASCO Annual Meeting Orlando. 2005 Abstract # 4542.
  • 38
    • 0037381437 scopus 로고    scopus 로고
    • Current Canadian experience with capecitabine: Partnering with patients to optimize therapy
    • Gerbrecht B. Current Canadian experience with capecitabine: Partnering with patients to optimize therapy. Cancer Nurs 2003;26:161-7.
    • (2003) Cancer Nurs , vol.26 , pp. 161-167
    • Gerbrecht, B.1
  • 39
    • 38349115491 scopus 로고    scopus 로고
    • Bayer. Nexavar prescribing information, 8/06 available at http://www.Nexavar.Com/wt/page/index. 2006.
    • Bayer. Nexavar prescribing information, 8/06 available at http://www.Nexavar.Com/wt/page/index. 2006.
  • 40
    • 0028784418 scopus 로고
    • Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study
    • Bertelli G GA, Forno G, et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study. J Clin Oncol 1995;13:2851-5.
    • (1995) J Clin Oncol , vol.13 , pp. 2851-2855
    • Bertelli, G.G.1    Forno, G.2
  • 41
    • 0035702431 scopus 로고    scopus 로고
    • Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors
    • Eng C MA, Fleming G, et al. Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. Ann Oncol 2001;12:1743-7.
    • (2001) Ann Oncol , vol.12 , pp. 1743-1747
    • Eng, C.M.1    Fleming, G.2
  • 42
    • 0025217908 scopus 로고
    • Pyridoxine therapy for palmar-plantar erythrodysesthesia assoicated with continuous 5-fluorouracil infusion
    • Fabian C MR, Lavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia assoicated with continuous 5-fluorouracil infusion. Invest New Drugs 1990;8:57-63.
    • (1990) Invest New Drugs , vol.8 , pp. 57-63
    • Fabian, C.M.1    Lavik, M.2
  • 43
    • 0027209407 scopus 로고
    • Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere
    • Vukelja S BW, Burris H, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 1993;85:1432-3.
    • (1993) J Natl Cancer Inst , vol.85 , pp. 1432-1433
    • Vukelja, S.B.1    Burris, H.2
  • 44
    • 3543080446 scopus 로고    scopus 로고
    • Oral dexamethasone attenuates pld-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies
    • Drake R LW, King M, et al. Oral dexamethasone attenuates pld-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 2004;94:320-4.
    • (2004) Gynecol Oncol , vol.94 , pp. 320-324
    • Drake, R.L.1    King, M.2
  • 45
    • 38349126085 scopus 로고    scopus 로고
    • Dramatic improvement of palmar plantar erythrodysesthesia(ppe) with oral prednisone
    • Elecronic letter
    • Jaber R DW, Wu S. Dramatic improvement of palmar plantar erythrodysesthesia(ppe) with oral prednisone. Ann Oncol 2007; Elecronic letter.
    • (2007) Ann Oncol
    • Jaber, R.1    DW, W.S.2
  • 46
    • 0028266986 scopus 로고
    • 5-flourouracil dermatitis prophylaxis with a nicotine patch
    • Abstract
    • Kingsley E. 5-flourouracil dermatitis prophylaxis with a nicotine patch. Ann Intern Med 1994;120:813 (Abstract).
    • (1994) Ann Intern Med , vol.120 , pp. 813
    • Kingsley, E.1
  • 47
    • 33744783431 scopus 로고    scopus 로고
    • Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction
    • Kara I SB, Erkisi M. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 2006;15:414-24.
    • (2006) Breast , vol.15 , pp. 414-424
    • Kara, I.S.1    Erkisi, M.2
  • 48
    • 0036985988 scopus 로고    scopus 로고
    • Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity (Abstract)
    • Lin E MJ, Ayers G. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity (Abstract). Oncology 2002;16:31-7.
    • (2002) Oncology , vol.16 , pp. 31-37
    • Lin, E.M.1    Ayers, G.2
  • 49
    • 34247606548 scopus 로고    scopus 로고
    • Panares R GAea. Bevacizumab in the management of solid tumors. Expert Rev Anticancer Therapy 2007;4:433-45.
    • Panares R GAea. Bevacizumab in the management of solid tumors. Expert Rev Anticancer Therapy 2007;4:433-45.
  • 51
    • 33746591262 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions
    • Morabito A DME, Di Maio M, et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. Oncologist 2006;11:753-64.
    • (2006) Oncologist , vol.11 , pp. 753-764
    • Morabito, A.D.1    Di Maio, M.2
  • 52
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib vs interferon alfa in metastatic renal cell cancer
    • Motzer R HT, Tomczak P, et al. Sunitinib vs interferon alfa in metastatic renal cell cancer. NEJM 2007;356:115-24.
    • (2007) NEJM , vol.356 , pp. 115-124
    • Motzer, R.H.1    Tomczak, P.2
  • 53
    • 33947423448 scopus 로고    scopus 로고
    • Approval summary: Sunitinib for the treatment of imatinib refractory or intolerance in gastrointestinal stromal tumors and advanced renal cell cancer
    • Goodman V RE, Dagher R, et al. Approval summary: Sunitinib for the treatment of imatinib refractory or intolerance in gastrointestinal stromal tumors and advanced renal cell cancer. Clin Cancer Res 2007;13:1367-73.
    • (2007) Clin Cancer Res , vol.13 , pp. 1367-1373
    • Goodman, V.R.1    Dagher, R.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.